TEVA PHARMACEUTICAL INDUSTRIES LIMITED Deferred Federal Income Tax Expense (Benefit)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVJF) reported Deferred Federal Income Tax Expense (Benefit) of $52.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-03.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-02-03
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED deferred federal income tax expense (benefit) for fiscal 2025 was $52.00M, a 21.21% decline from fiscal 2024.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED deferred federal income tax expense (benefit) for fiscal 2024 was $66.00M.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED deferred federal income tax expense (benefit) for fiscal 2023 was -$438.00M.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $52.00M 10-K · filed 2026-02-03 |
| 2024-12-31 | $66.00M 10-K · filed 2026-02-03 |
| 2023-12-31 | -$438.00M 10-K · filed 2026-02-03 |